Adequate control of lipids is a cornerstone in the management of coronary heart disease. Numerous studies have demonstrated the effectiveness of HMG-Co A reductase inhibitors (statins) in controlling LDL-C. Unfortunately, the effect of statins on other lipid parameters, such as HDL-C and triglycerides, is not as robust. Emerging evidence suggests that these other lipid parameters may contribute to residual cardiovascular risk. The recent release of fenofibric acid offers a potential therapy which can be used in conjunction with statins to achieve an optimal lipid profile. Clinical trials have demonstrated fenofibric acid to be safe for use as dual therapy with low and moderate dose statins. The following article will address the safety and efficacy of fenofibric acid in the treatment of lipid disorders, both alone and as combination therapy with statins. Additionally, the potential role of fenofibric acid in the management of the complex cardiovascular patient with abnormal lipid parameters will be evaluated.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
Publishing in Clinical Medicine Reviews in Vascular Health was a pleasant experience. The process was fast and fair. The staff were very professional and we were well informed of the progress of the manuscript.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)